wmm, Author at Invivoscribe

About wmm

This author has not yet filled in any details.
So far wmm has created 30 blog entries.

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

wmm2022-12-29T21:22:21+00:00November 15th, 2022|2022 Publications, Featured Publications, Publications|

Development and Implementation of an Automated and Highly Accurate Reporting Process for NGS-based Clonality Testing

wmm2023-01-16T21:30:16+00:00November 2nd, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

High-Throughput Sequencing of TCR Gene Rearrangements as a Useful Tool for Identifying and Tracking Minimal/Measurable Residual Disease (MRD) in Lymphoid Malignancies

wmm2023-01-16T21:27:56+00:00November 2nd, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

NGS-based Clinical Assessment of B- and T-cell Clonality and MRD Determination

wmm2022-10-27T04:25:21+00:00October 26th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML

wmm2022-10-24T14:57:12+00:00October 24th, 2022|2022 Press Releases, Press Releases|

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

wmm2022-12-29T21:19:31+00:00June 4th, 2022|2022 Publications, Featured Publications, Publications|

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

wmm2023-01-08T18:20:36+00:00May 30th, 2022|2022 Publications, Featured Publications, Publications|

Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine

wmm2022-05-09T17:27:05+00:00May 9th, 2022|2022 Press Releases, Press Releases|

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

wmm2022-01-06T05:38:03+00:00January 4th, 2022|2022 Publications, Featured Publications, Publications|

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL

wmm2022-01-08T23:37:03+00:00December 28th, 2021|2021 Publications, Publications|

Plan for a Successful International Drug Approval with Early Development of the Accompanying CDx

wmm2022-01-04T04:43:02+00:00December 8th, 2021|2021 Publications, Publications|

Machine Learning Algorithms Accelerate Throughput of a Flow – Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platform

wmm2022-01-30T21:35:17+00:00November 5th, 2021|2021 Publications, Publications|

Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System

wmm2021-06-24T18:20:34+00:00June 24th, 2021|2021 Press Releases, Press Releases|

Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China

wmm2021-06-03T20:36:18+00:00June 3rd, 2021|2021 Press Releases, Press Releases|

Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphoma

wmm2023-01-10T16:48:18+00:00April 28th, 2021|2022 Publications, Featured Publications, Publications|

Invivoscribe To Present At Biotech Showcase™ 2019 In San Francisco

wmm2021-02-26T19:10:54+00:00January 3rd, 2019|2019 Press Releases, Press Releases|

Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Software

wmm2021-02-26T19:12:40+00:00November 7th, 2017|2017 Press Releases, Press Releases|

Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.

wmm2021-02-26T19:12:46+00:00August 1st, 2017|2017 Press Releases, Press Releases|

FDA approves new combination treatment for acute myeloid leukemia

wmm2021-02-26T19:12:55+00:00April 28th, 2017|2017 Press Releases, Press Releases|

Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AML

wmm2021-02-26T19:13:02+00:00April 28th, 2017|2017 Press Releases, Press Releases|

Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapies

wmm2021-02-26T19:13:49+00:00March 28th, 2017|2017 Press Releases, Press Releases|

Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Software

wmm2021-02-26T19:13:58+00:00February 28th, 2017|2017 Press Releases, Press Releases|

Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kits

wmm2021-02-26T19:14:04+00:00February 14th, 2017|2017 Press Releases, Press Releases|

Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits

wmm2021-02-26T19:14:11+00:00January 31st, 2017|2017 Press Releases, Press Releases|

Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis

wmm2021-02-26T19:14:23+00:00November 14th, 2016|2016 Press Releases, Press Releases|

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

About wmm

Title

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing